AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17219967
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of Triptorelin (3.75 mg) at 4-week intervals
Trial: 10793603
Drug: Quinaprilat 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinaprilat 0.02 mg kg‐1 (group A)
Trial: 10793603
Drug: Quinaprilat 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinaprilat 0.04 mg kg‐1 (group B)
Trial: 10793603
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (group C)
Trial: 30642076
Drug: TNF-α inhibitors
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α inhibitors (TNFi)
Trial: 30373740
Drug: Curcumin (2000-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (2000-mg doses 8 times over 4 days)
Trial: 27829388
Drug: Maternal Oral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal Oral Screening (MOS) tool
Trial: 27829388
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Impact Profile (OHIP-14)
Trial: 24797294
Drug: Antimicrobial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial treatment (40 mg/kg of amoxicillin‐clavulanate per day for 7 days)
Trial: 22039291
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) containing 0.5 mg NE and 0.035 mg EE
Trial: 22039291
Drug: OC plus
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC plus telaprevir (750 mg every 8 hours)
Trial: 20561115
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene education (ST)
Trial: 12040477
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg rhGM-CSF solution (group A, n = 18)
Trial: 12040477
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (group B, n = 23)
Trial: 2548554
Drug: Cilazapril 0.5
RxNorm normalized name: cilazapril 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 0.5 mg
Trial: 2548554
Drug: Cilazapril 1
RxNorm normalized name: cilazapril 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1 mg
Trial: 2548554
Drug: Cilazapril 0.5
RxNorm normalized name: cilazapril 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 0.5 mg daily (multiple dose phase)
Trial: 2548554
Drug: Cilazapril 1
RxNorm normalized name: cilazapril 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1 mg daily (multiple dose phase)
Trial: 31228593
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (ES) of antagonist muscles plus single ES session on injected muscles
Trial: 16960930
Drug: Tacrolimus 3
RxNorm normalized name: Tacrolimus 300 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 3 mg once daily
Trial: 16960930
Drug: Mizoribine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine 50 mg three times daily
Trial: 8372768
Drug: MR arthrography
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR arthrography with 40-50 ml of a 1:100 solution of gadopentetate dimeglumine in saline
Trial: 3534730
Drug: Cefoperazone 1
RxNorm normalized name: cefoperazone 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone 1 g IV every 8 hours for 5 days
Trial: 3534730
Drug: Cotrimoxazole 800
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole 800 mg sulfamethoxazole and 160 mg trimethoprim every 12 hours for 5 days
Trial: 30634046
Drug: Design systems
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Design systems that collect data for treatment personalization
Trial: 29424799
Drug: AS04-HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-HPV-16/18 vaccine (2 doses)
Trial: 29424799
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1 dose of measles-mumps-rubella and diphtheria-tetanus-acellular-pertussis vaccines)
Trial: 26666342
Drug: Procalcitonin ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin ≥ 0.20 ng/mL (N=104)
Trial: 26666342
Drug: Procalcitonin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin < 0.20 ng/mL
Trial: 24462855
Drug: Systemic methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic methotrexate (MTX) combined with ultrasound-guided local injection of potassium chloride (KCl) or MTX
Trial: 20642545
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg (morning dosing)
Trial: 20642545
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg (evening dosing)
Trial: 20642545
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of Vildagliptin 100 mg
Trial: 17715164
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 100-125 ppm carbon monoxide (CO) for 2 hours per day over 4 consecutive days.
Trial: 12065335
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI), 300 mg bid
Trial: 12065335
Drug: Oral quinolone
RxNorm normalized name: quinoline yellow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinolone antibiotics (primarily ciprofloxacin)
Trial: 12065335
Drug: TSI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSI therapy
Trial: 9537270
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (3 doses at 2, 3, and 4 months of age)
Trial: 2523611
Drug: Goserelin (Zoladex),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (Zoladex), 3.6 mg sc/28 d
Trial: 2523611
Drug: Diethylstilbestrol (DES),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES), 1 mg tid
Trial: 904400
Drug: Challenge food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge food tests administered to patients.
Trial: 31937553
Drug: Active respiratory
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active respiratory muscle training (RMT) performed twice daily for 6 weeks
Trial: 29982701
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone) at adequate doses
Trial: 28294136
Drug: morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (10 mg)
Trial: 28294136
Drug: naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone (50 mg)
Trial: 11249051
Drug: High-dose thiotepa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thiotepa (600 mg/m2) + melphalan (160 mg/m2) with hemopoietic support
Trial: 11249051
Drug: High-dose thiotepa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thiotepa and melphalan
Trial: 22850489
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy (WBC) combined with physical therapy modalities and joint mobilization
Trial: 22850489
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy modalities and passive joint mobilization of the shoulder (non-WBC group)
Trial: 21118164
Drug: Ivabradine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine added to standard therapy
Trial: 21118164
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of SA and CHF
Trial: 10960460
Drug: Triple antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiviral therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily, amantadine 200 mg daily) for 12 months
Trial: 10960460
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily) for 12 months
Trial: 10960460
Drug: Triple antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiviral therapy
Trial: 6342543
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment together with intrathecal equine antitetanus serum
Trial: 6342543
Drug: Parenteral intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral intramuscular diazepam as a sedative
Trial: 6342543
Drug: Paraldehyde as
RxNorm normalized name: Paraldehyde
DrugBank: Paraldehyde (DB09117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraldehyde as a sedative
Trial: 25169631
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg, tid
Trial: 25169631
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment (low‐flow oxygen, low‐salt diet therapy, cardiac therapy)
Trial: 16820805
Drug: HydraBrush Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HydraBrush Oral Health System (OHS)
Trial: 10937603
Drug: Pharmacotherapy (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (fluoxetine or bupropion)
Trial: 6840904
Drug: Drug-free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free period
Trial: 30700278
Drug: Song of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Song of Life (SOL) music therapy
Trial: 22453248
Drug: oral glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral glycerol = sports drink, water, and glycerol
Trial: 22453248
Drug: IV with
RxNorm normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV with oral glycerol = half as normal saline, half as sports drink, water, and glycerol
Trial: 22453248
Drug: oral =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral = sports drink and water
Trial: 20400004
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO(4)) infusion
Trial: 17511361
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sandblasting with tribochemical silica coating
Trial: 17511361
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sandblasting and tribochemical silica coating
Trial: 12162381
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBO2) - 40 sessions over 2 months, 1 hour exposure to 100% oxygen at 1.75 ATA
Trial: 12162381
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment - 40 sessions over 2 months, 1 hour exposure to air at 1.3 ATA
Trial: 30306805
Drug: Neurodynamic techniques
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodynamic techniques (20 sessions, twice weekly)
Trial: 19546818
Drug: Gemcitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1250 mg/m2 in 20 to 30 minutes) + Cisplatin (75 mg/m2 on day 2)
Trial: 19546818
Drug: Gemcitabine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2)
Trial: 19546818
Drug: Gemcitabine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2) in patients with squamous carcinoma
Trial: 15193818
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + Simvastatin 20 mg daily
Trial: 11463131
Drug: Chewing dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing dextrose tablets
Trial: 9874905
Drug: High‐intensity, socially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐intensity, socially demanding day treatment program (DTP)
Trial: 7978377
Drug: Sperm preparation
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sperm preparation using immunobeads
Trial: 2926575
Drug: Spironolactone-hydrochlorothiazide (Aldactazide)
RxNorm normalized name: hydrochlorothiazide / spironolactone Oral Tablet [Aldactazide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone-hydrochlorothiazide (Aldactazide) at 3 mg/kg/day for 6 to 8 days (n = 12)
Trial: 2926575
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 9)
Trial: 4593554
Drug: Clonidine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (25 to 75 mcg twice daily)
Trial: 31397866
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (rotator cuff surgery followed by approximately 4 months of postoperative rehabilitation)
Trial: 31397866
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (approximately 3‐month standardized physical therapy program)
Trial: 28244415
Drug: Liquid honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid honey (10 mL, 4 times a day)
Trial: 28244415
Drug: Lozenge honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge honey (10 mL, 4 times a day)
Trial: 25529033
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of IGU and methotrexate
Trial: 22812912
Drug: Protocol 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 1: acid-etching (dentin) + silica coating (composite) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Trial: 22812912
Drug: Protocol 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 2: silica coating (composite) + acid-etching (dentin) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Trial: 22812912
Drug: Protocol 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 3: acid-etching (dentin) + primer (dentin) + silanization (composite) + bonding agent (dentin + composite)
Trial: 15660766
Drug: Zonisamide 300
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 300 mg/day
Trial: 21166480
Drug: Zonisamide 400
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 400 mg/day
Trial: 21166480
Drug: Zonisamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (300 and 400 mg/day)
Trial: 18377143
Drug: Hypnotic taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotic taper intervention with self-help treatment for insomnia
Trial: 18377143
Drug: Hypnotic taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotic taper intervention without self-help treatment for insomnia
Trial: 17178982
Drug: 0.1% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 1)
Trial: 17178982
Drug: 0.1% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 2)
Trial: 17178982
Drug: 0.1% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluocinonide cream applied once daily for 2 weeks (all cohorts)
Trial: 17178982
Drug: 0.1% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks (all cohorts)
Trial: 17178982
Drug: 0.1% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluocinonide cream applied once daily for 2 weeks
Trial: 17178982
Drug: 0.1% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluocinonide cream applied twice daily for 2 weeks
Trial: 10783018
Drug: Negative nasopharyngeal
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NT‐AOM
Trial: 10783018
Drug: Negative nasopharyngeal
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NR‐AOM
Trial: 1458764
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole (20mg)
Trial: 1458764
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole (40mg)
Trial: 1458764
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral omeprazole
Trial: 6327543
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 600 mg intramuscularly daily for 12 days
Trial: 6327543
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg daily for 21 days
Trial: 6327543
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sodium stibogluconate and rifampin
Trial: 29804728
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to frontline therapy
Trial: 24812022
Drug: Non-assigned treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-assigned treatments (pharmacotherapy, behavioral, alternative, non-study Internet)
Trial: 20482243
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro pen
Trial: 19018255
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of individual support and group rehabilitation
Trial: 9690944
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of erythropoietin (Epoetin beta)
Trial: 8080985
Drug: RGD peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGD peptide matrix treatment
Trial: 8080985
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus RGD peptide matrix
Trial: 2753986
Drug: Hydergine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine (2 mg, single oral dose)
Trial: 2753986
Drug: Hydergine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine (2 mg, 3 times daily, chronic treatment for 4-12 weeks)
Trial: 2753986
Drug: Hydergine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine (2 mg, 3 times daily, chronic treatment for 4-104 weeks)
Trial: 29203842
Drug: Clomipramine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 15 mg/day
Trial: 29203842
Drug: Clomipramine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 30 mg/day
Trial: 23543311
Drug: Weekly PEG‐IFNα‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly PEG‐IFNα‐2a (group C)
Trial: 23543311
Drug: Biweekly therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly therapy (group D)
Trial: 20804630
Drug: Cranberry powder
RxNorm normalized name: Cranberry powder/extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry powder (1500 mg per day for 6 months)